Sandoz Group AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SDZNY research report →
Companywww.sandoz.com
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics.
- CEO
- Richard Saynor
- IPO
- 2023
- Employees
- 22,049
- HQ
- Rotkreuz, CH
Price Chart
Valuation
- Market Cap
- $36.14B
- P/E
- 39.26
- P/S
- 3.25
- P/B
- 3.84
- EV/EBITDA
- 24.65
- Div Yield
- 1.21%
Profitability
- Gross Margin
- 47.19%
- Op Margin
- 14.60%
- Net Margin
- 8.22%
- ROE
- 10.09%
- ROIC
- 7.81%
Growth & Income
- Revenue
- $11.15B · 7.36%
- Net Income
- $919.12M · 91812.09%
- EPS
- $2.13 · 0.00%
- Op Income
- $1.71B
- FCF YoY
- 1250.00%
Performance & Tape
- 52W High
- $94.15
- 52W Low
- $48.05
- 50D MA
- $81.32
- 200D MA
- $72.43
- Beta
- 0.53
- Avg Volume
- 36.34K
Get TickerSpark's AI analysis on SDZNY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SDZNY Coverage
We haven't published any research on SDZNY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SDZNY Report →